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Parameter
ST-Exp
70%(n=672)
ST-Exp 60-
70%(n=159)
ST-Exp
<60%(n=58) p-value
ST-Exp (%) 82.1 [76.7,
86.7]
65.8 [63.7,
68.0]
55.0 [51.4,
57.4]
<0.0001
MSA (mm2) 6.5 [5.0, 8.2] 5.2 [4.1, 6.5] 4.1 [3.2, 4.9] <0.0001
Lesion length
(mm)
21.0 [15.4,
30.2]
32.1 [22.2,
46.7]
47.5 [32.8,
62.0]
<0.0001
Plaque burden
at MLA (%)
77.6 [69.2,
83.7]
77.7 [69.5,
83.9]
80.3 [75.2,
85.2]
0.18
Superﬁcial arc
of calcium ()
87 [47, 145] 100 [68, 171] 159 [90, 230] <0.0001
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM
P
O
S
T
E
R
Sa signiﬁcant higher rates of malapposed strut, particularly toward the SB ostium (40.6 
6.0%versus 26.0 5.7%, p¼0.0005), aswell as a higher SB lumen residual stenosis than
after mid-distal recrossing (39.7  7.1 % versus 18.9  8.0 %, p < 0.0001). In-vivo
Optical Coherence Tomography (OCT) analysis on 52 patients undergoing elective
treatment of bifurcation lesions using provisional stenting showed that using OCT to
guide cell recrossing is feasible and can reduce signiﬁcantly strut malapposition in
bifurcation. Patients who were treated using OCT-guided distal recrossing had a signiﬁ-
cantly lower number of malapposed stent struts, especially in the quadrants towards the
SB ostium than in the angiography-guided group (9.5% vs 42.3%, p<0.0001).
Conclusions: Optimal distal cell recrossing of the guidewire is critical to ensure
a successful stent optimization in bifurcation PCI.
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Background: The DESolve Bioresorbable Scaffold is a novel drug-eluting device
combining a PLLA-based scaffold coated with a bioresorbable polylactide-based
polymer and a potent anti-proliferative sirolimus metabolite, Novolimus. The drug dose
is 5 mcg per mm of scaffold length. An early beneﬁt with regard to vessel restoration is
a potential feature of this unique technology. The aim of this study is to assess the serial
changes in the vessel treated with the DESolve scaffold using IVUS technology.
Methods: The DESolve NX is a pivotal, prospective and multicentre clinical trial, which
enrolled 126 patients with de novo coronary lesions treated with a single scaffold
available in three diameters (3.0, 3.25 and 3.5) and two lengths (14 and 18 mm). The ﬁrst
46 patients enrolled in this trial were part of an IVUS sub-study, which consisted of
a paired analysis of the automatic pullbacks performed at the end of the baseline
procedure and at six-month follow-up (an additional 24 month follow up will also be
performed). All analyses are being performed by an independent IVUS core lab.
Results: The mean age of the study population was 62 years, 68% of which were men
and 21% had diabetes. Pre procedure reference vessel lesion length and diameter were
11.2  3.8mm and 3.06  0.31, respectively. 40 of the 46 patients enrolled in the
IVUS sub study had serial analyses available at 6 months that demonstrated
a signiﬁcant increase in mean lumen (D 9.0%, p ¼ <0.001), scaffold (D 15.7%,
p ¼ <0.001) and vessel (D 16.8 %, p ¼ <0.001) areas between baseline and 6 months
and low % volume obstruction (5.05%) with no case of late acquired scaffold
incomplete apposition or aneurysm formation.
Conclusions: The DESolve scaffold is the ﬁrst scaffold to demonstrate lumen area
enlargement with no chronic recoil at 6 month follow up with no evidence of aneu-
rysms. Serial IVUS results at 6 months showed effective neointimal suppression and
no late acquired strut malapposition suggesting the natural ability of the scaffolded
vessel to remodel at 6 months.
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Background: While a smaller minimum stent cross-sectional area (MSA) predicts
adverse events (stent restenosis and thrombosis), predictors of stent underexpansion
have not been fully investigated.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrMethods: ADAPT-DES was a prospective, multicenter, registry of 8,583 consecutive
pts with undergoing PCI with DES. Among 2064 pts enrolled in a pre-speciﬁed
intravascular ultrasound (IVUS) substudy, 769 pts with 889 lesions were examined by
both pre and post-PCI IVUS. Stent expansion (ST-Exp) was calculated as MSA
divided by average of proximal and distal stent edge lumen area; %ST-Exp was
divided into (1) 70% (adequate expansion), (2) 60-70% (moderate underexpansion),
and (3) <60% (severe underexpansion).
Results: Lesion length was longer and maximum arc of superﬁcial calcium was
greater in the severe underexpansion group than in the other 2 groups (Table). These
ﬁndings were independent of vessel size and were also similar when stent expansion
was divided into tertiles: highest tertile of stent expansion (ST-exp >83%), middle
tertile (73%-83%), and lowest tertiles (ST-exp <73%). Multiple logistic regression
analysis revealed that lesion length [OR 1.80 per 10 mm (1.54, 2.09), p<0.0001] and
maximum arc of superﬁcial calcium [OR 1.13 per 90 (1.30, 2.00), p¼0.006] were
independently associated with severe stent underexpansion (ST-Exp<60%). ROC
curve analysis showed that cut-off values of lesion length and maximum arc of
superﬁcial calcium that best predicted stent expansion <60% (severe underexpansion)
were 42.0 mm and 127. Conversely, plaque burden was unrelated to stent expansion.
Conclusions: Lesion length and the extent of superﬁcial calcium are the strongest
determinants of stent underexpansion.TCT-598
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Background: Incomplete stent apposition (ISA) is a potential factor in the subsequent
development of later adverse events, including stent thrombosis, in patients treated
with drug-eluting stents (DES). We assessed the incidence and mechanisms of ISA in
patients with ST-segment Elevation Myocardial Infarction (STEMI) treated with
a biolimus-eluting Nobori stent (BES) or a sirolimus-eluting Cypher stent (SES).
Methods: In the Randomized Comparison of Biolimus-Eluting Biodegradable Poly-
mer Coated Stent and Durable Polymer Sirolimus-Eluting Stent in Unselected Patients
(SORT OUT V) trial, a prespeciﬁed intravascular ultrasound (IVUS) substudy
enrolled 116 STEMI patients (57 BESs and 59 SESs) treated with PPCI where post-
procedure and 12-month follow-up imaging data were available. The vascular
response and inﬂuence of remodeling (changes in external elastic membrane (EEM)
cross sectional area (CSA)) in “acute”, “resolved”, and “late acquired” ISA was
evaluated.
Results: Post-intervention ISA occurred in 22 (19.0%) stented lesions (15.8% BES
and 22.0% SES, p¼ns). Of these, 7 (31.8%) resolved at follow-up without signiﬁcant
remodeling (post-intervention EEM CSA 19.7 mm2 (interquartile range (IQR) 17.0 to
23.5 mm2) vs. follow-up EEM CSA 20.9 mm2 IQR 17.8 to 23.5 mm2), p¼ns. Plaque
CSA increased from post-intervention 6.7 mm2 (IQR 5.5 to 8.9 mm2) to follow-up
plaque CSA 10.0 mm2 (IQR 9.2 to 12.4 mm2), p¼0.018. At follow-up late acquired
ISA was seen in 19 (16.4%) stented lesions (14.0% BES and 18.6% SES, p¼ns). In
patients with late acquired ISA, the mechanism was positive remodeling in 73.7% of
the stented lesions (post-intervention EEM CSA 21.0 mm2 (IQR 13.5 to 26.9 mm2)
vs. follow-up EEM CSA 27.4 mm2 (IQR 18.6 to 31.3 mm2), p¼0.001, and maximum
ISA CSA was 3.5 mm2 (IQR 1.3 to 5.8 mm2). In 26.3% of the patients with late
acquired ISA, negative remodeling and plaque/thrombus resolution was seen.
Conclusions: In STEMI patients "acute" ISA resolved in one third of the stented
lesions, mainly due to plaque progression. "Late acquired" ISA was predominantly
due to positive remodeling.acts/POSTER/Intravascular Imaging and PCI B181
